Editorial: chronic hepatitis C with metabolic dysfunction-associated fatty liver disease - a model for adoption of Sustainable Development Goal 3

Affiliations

Editorial

Oyekoya Ayonrinde et al. Aliment Pharmacol Ther. 2023 Jan.

. 2023 Jan;57(2):270-271.

doi: 10.1111/apt.17270. Epub 2022 Dec 5.

¹ Department of Gastro and Hepatology, Fiona Stanley Hospital, Muroch, Western Australia, Australia.

No abstract available

Comment on

Increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis with concurrent fatty liver.
Kim MN, Han K, Yoo J, Hwang SG, Ahn SH. Kim MN, et al. Aliment Pharmacol Ther. 2022 Jan;55(1):97-107. doi: 10.1111/apt.16706. Epub 2021 Nov 24. Aliment Pharmacol Ther. 2022. PMID: 34820871
A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach.
Lazarus JV, Mark HE, Colombo M, Demaio S, Dillon JF, George J, Hagström H, Hocking S, Lee N, Nieuwenhuijsen MJ, Rinella ME, Romero-Gomez M, Soriano JB, Schattenberg JM, Tacke F, Tsochatzis EA, Valenti L, Zelber-Sagi S, Ashworth Dirac M, Huang TT. Lazarus JV, et al. Aliment Pharmacol Ther. 2022 Jan;55(2):234-243. doi: 10.1111/apt.16720. Epub 2021 Dec 5. Aliment Pharmacol Ther. 2022. PMID: 34866201
Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world.
Henry L, Paik J, Younossi ZM. Henry L, et al. Aliment Pharmacol Ther. 2022 Sep;56(6):942-956. doi: 10.1111/apt.17158. Epub 2022 Jul 26. Aliment Pharmacol Ther. 2022. PMID: 35880713 Review.
Prevalence and clinical characteristics of patients with metabolic dysfunction-associated fatty liver disease with hepatitis C virus infection-a population-based study.
Attia D, Abdel Alem S, El-Akel W, Abdel-Razek W, Eslam M, Fouad Y, Waked I. Attia D, et al. Aliment Pharmacol Ther. 2022 Dec;56(11-12):1581-1590. doi: 10.1111/apt.17233. Epub 2022 Sep 27. Aliment Pharmacol Ther. 2022. PMID: 36168675

1. Hui JM, Kench J, Farrell GC, Lin R, Samarasinghe D, Liddle C, et al. Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol. 2002;17(8):873-81. https://doi.org/10.1046/j.1440-1746.2002.02813.x
1. Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022;7(5):396-415. https://doi.org/10.1016/S2468-1253(21)00472-6
1. Henry L, Paik J, Younossi ZM. Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world. Aliment Pharmacol Ther. 2022;56(6):942-56. https://doi.org/10.1111/apt.17158
1. Chan KE, Koh TJL, Tang ASP, Quek J, Yong JN, Tay P, et al. Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-analysis and systematic review of 10 739 607 individuals. J Clin Endocrinol Metab. 2022;107(9):2691-700. https://doi.org/10.1210/clinem/dgac321
1. Fouad Y, Lazarus JV, Negro F, Peck-Radosavljevic M, Sarin SK, Ferenci P, et al. MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective. Aliment Pharmacol Ther. 2021;53(10):1080-9. https://doi.org/10.1111/apt.16346